Insider Transactions in Q1 2024 at Kymera Therapeutics, Inc. (KYMR)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2024
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
71,764
-0.47%
|
$2,870,560
$40.39 P/Share
|
|
Mar 14
2024
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
55,779
-0.36%
|
$2,231,160
$40.63 P/Share
|
|
Mar 13
2024
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
139,255
-1.31%
|
$5,848,710
$42.51 P/Share
|
|
Mar 13
2024
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Indirect |
24,165
-1.42%
|
$1,014,930
$42.51 P/Share
|
|
Mar 13
2024
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Direct |
115,090
-1.2%
|
$4,833,780
$42.51 P/Share
|
|
Mar 12
2024
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
162,918
-1.49%
|
$6,842,556
$42.23 P/Share
|
|
Mar 12
2024
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Indirect |
28,271
-1.61%
|
$1,187,382
$42.23 P/Share
|
|
Mar 12
2024
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Direct |
134,647
-1.37%
|
$5,655,174
$42.23 P/Share
|
|
Mar 11
2024
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
51,184
-0.46%
|
$2,200,912
$43.09 P/Share
|
|
Mar 11
2024
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Indirect |
8,882
-0.5%
|
$381,926
$43.09 P/Share
|
|
Mar 11
2024
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Direct |
42,302
-0.43%
|
$1,818,986
$43.09 P/Share
|
|
Mar 04
2024
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,344
-1.14%
|
$140,448
$42.35 P/Share
|
|
Mar 04
2024
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,934
-0.9%
|
$165,228
$42.35 P/Share
|
|
Mar 01
2024
|
Jared Gollob Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,375
+19.74%
|
-
|
|
Mar 01
2024
|
Ellen Chiniara Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,755
+27.99%
|
-
|
|
Mar 01
2024
|
Jeremy G Chadwick Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,425
+22.31%
|
-
|
|
Mar 01
2024
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+17.6%
|
-
|
|
Feb 27
2024
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
400
-0.53%
|
$18,000
$45.0 P/Share
|
|
Feb 27
2024
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+0.53%
|
$800
$2.08 P/Share
|
|
Feb 21
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
4,385
-100.0%
|
$171,015
$39.05 P/Share
|
|
Feb 21
2024
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
4,385
+50.0%
|
$43,850
$10.34 P/Share
|
|
Feb 20
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
615
-100.0%
|
$23,985
$39.07 P/Share
|
|
Feb 20
2024
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
615
+50.0%
|
$6,150
$10.34 P/Share
|
|
Feb 09
2024
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
46,137
-20.53%
|
$1,614,795
$35.74 P/Share
|
|
Feb 09
2024
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,137
+27.63%
|
$92,274
$2.08 P/Share
|
|
Jan 23
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$300,000
$30.05 P/Share
|
|
Jan 23
2024
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$100,000
$10.34 P/Share
|
|
Jan 04
2024
|
Ellen Chiniara Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,295
-8.79%
|
$72,490
$22.58 P/Share
|
|
Jan 02
2024
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+1.44%
|
$18,000
$2.08 P/Share
|